Standard BioTools Set to Release Earnings Reports

Standard BioTools (NASDAQ:LAB) is expected to announce its quarterly earnings after the market closes on Wednesday, February 26. Analysts predict that the company will report an earnings loss of ($0.03) per share along with revenues estimated at $43.03 million for this period. Investors and interested parties can register for the upcoming earnings conference call using the provided link.

Recent Stock Performance

On Wednesday, NASDAQ:LAB opened at $1.40. The stock has shown moderate fluctuation with a fifty-day moving average of $1.73 and a two-hundred-day moving average at $1.82. Over the past year, Standard BioTools has experienced a twelve-month low of $1.17 and a high of $3.04. The company's market capitalization currently stands at approximately $521.16 million. It has a price-to-earnings ratio of -1.97 and a beta value of 1.57, indicating that the stock is more volatile compared to the market average.

Analysts' Insights

In a recent analysis, TD Cowen has reduced its price target for Standard BioTools from $2.75 to $2.50 while maintaining a "buy" rating on the stock. This adjustment reflects their assessment of the company's performance and market position.

About Standard BioTools

Standard BioTools Inc. operates globally, offering a range of instruments, consumables, reagents, and software services designed primarily for researchers and laboratory environments. The company is divided into two key segments: Proteomics and Genomics. Among their notable products are the CyTOF XT System, which facilitates automated single-cell analysis, and the Hyperion XTi imaging system, renowned for its spatial biology capabilities.

Standard, BioTools, Earnings